January 15, 2019
DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of bovine collagen and biphasic, hydroxyapatite/ß-tricalcium phosphate granules designed to produce a reliable, porous scaffold and sustained osteoconductivity throughout the bone remodeling process.
The Bioventus research and development group led a cross functional team to develop OSTEOMATRIX+ which has more unique handling properties, including improved moldability, flexibility and versatility, than its predecessor.
“OSTEOMATRIX+ represents the first of several next generation products that will be added to the Bioventus portfolio in the next five years,” said Tony Bihl, CEO, Bioventus. “We will provide more diverse orthobiologic offerings for hospitals and efficacious solutions for both surgeons and their patients, as we continue to grow and serve these markets.”
OSTEOMATRIX+ is available now from distributors nationwide. Visit www.BioventusSurgical.com to learn more.
Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The orthobiologic products from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.
Bioventus, the Bioventus logo and OSTEOMATRIX+ are registered trademarks of Bioventus LLC.
Summary of Indications for Use
OSTEOMATRIX+ is a bone graft substitute intended for use in bony voids or gaps of the skeletal system not intrinsic to the stability of the bony structure. These osseous defects may be surgically created or result from traumatic injury to the bone. OSTEOMATRIX+ is indicated to be combined with autologous bone marrow aspirate and packed into osseous defects of the extremities, pelvis and posterolateral spine. When used in the posterolateral spine, OSTEOMATRIX+ is to be used as an autograft extender. The device resorbs and is replaced by host bone during the healing process.
OSTEOMATRIX+ is not designed or sold for any use except as indicated. Do not use OSTEOMATRIX+ in the presence of any contraindication. OSTEOMATRIX+ is contraindicated where the device is intended as structural support in the skeletal system. OSTEOMATRIX+ must not be used in patients with a history of anaphylaxis, history of multiple allergies, known allergies to bovine collagen, or patients that are being treated for desensitization to meat products. Other conditions representing contraindications include: Necrosis or infection at the graft site, Malignant tumors, Intra-articular implantations, Severe vascular or neurological disease proximal to the graft site, Hypercalcemia, abnormal calcium metabolism, Inflammatory bone disease such as osteomyelitis, Metabolic or systemic bone disorders that affect, bone or wound healing, Patients unwilling or incapable of following post-operative instructions.
Please refer to the package insert for a complete listing of contraindications, warnings and precautions, and instructions for use.